Telesis Bio, Inc.
TBIO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $3 | $7 |
| % Growth | 1% | -54.9% | -50.7% | – |
| Cost of Goods Sold | $1 | $2 | $3 | $3 |
| Gross Profit | $1 | -$1 | $0 | $4 |
| % Margin | 64.4% | -51.5% | 7.9% | 58.7% |
| R&D Expenses | $2 | $2 | $3 | $3 |
| G&A Expenses | $3 | $6 | $5 | $4 |
| SG&A Expenses | $4 | $7 | $6 | $7 |
| Sales & Mktg Exp. | $1 | $2 | $2 | $4 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $6 | $11 | $9 | $10 |
| Operating Income | -$5 | -$10 | -$9 | -$6 |
| % Margin | -349.7% | -675.7% | -247.7% | -87.3% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$12 |
| Pre-Tax Income | -$6 | -$12 | -$9 | -$18 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$13 | -$9 | -$18 |
| % Margin | -424.1% | -811.9% | -251.1% | -253.5% |
| EPS | -3.92 | -7.62 | -0.29 | -0.59 |
| % Growth | 48.6% | -2,527.6% | 50.8% | – |
| EPS Diluted | -3.83 | -7.62 | -0.29 | -0.59 |
| Weighted Avg Shares Out | 2 | 2 | 30 | 30 |
| Weighted Avg Shares Out Dil | 2 | 2 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$5 | -$11 | -$7 | -$16 |
| % Margin | -298.7% | -680.3% | -210.6% | -229.6% |